Certara Launches Drug Development Consulting Services for Asia

Certara Launches Drug Development Consulting Services for Asia
Hidefumi Kasai Joins Certara's Pharsight Scientific Consulting Services Team

ST. LOUIS, Apr 01, 2013 (BUSINESS WIRE) -- Certara(TM) (headquartered in St. Louis, MO; Location of Japan office: Minato-ku, Tokyo), leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, today welcomed Hidefumi Kasai to lead the Pacific Rim division of Pharsight Consulting Services.

"The expansion of Pharsight Consulting Services in Japan is a significant milestone in Certara's vision to make Model Based Drug Development more easily available in the Pacific Rim. We are excited to welcome Mr. Kasai and believe his experience in PK/PD modeling and simulation, and Model Based Drug Development, will be of significant benefit to our customers," said Hironori Katsuse, Certara's General Manager Pacific Rim, in making the announcement.

After starting his career at Dainippon Pharmaceutical Co., Ltd. in 1992, Mr. Kasai worked as a research Associate at Clinical PK/PD Research Center, Pharmaceutical Department, School of Medicine, Keio University from 2002, and joined BELLSYSTEM24, Inc. (currently spun off into Bell Medical Solutions, Inc.) in 2006. In addition to having 20 years of experience in population PK/PD and statistical analyses in both nonclinical and clinical drug development, he has contributed to the development of the Model Based Drug Development (MBDD) approach through a variety of related academic societies.

The Pharsight Consulting Services team is the world's largest and most proficient PK/PD consulting group which supports strategic decision-making and regulatory support in drug development. Based in Japan, Mr. Kasai will closely collaborate with Certara's global team to engage in modeling of drug candidates by utilizing early clinical study data.

For more information about Certara's Pharsight Consulting Services, visit www.certara.com or www.certara.co.jp.

About Certara

Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation with scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives.


SOURCE: Certara

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.